Valeant's Goldman Connection: A CFO Schooled on Wall Street

Updated on
  • Schiller was key architect behind drug company's acquisitions
  • He resigned after Allergan deal fell apart, remains on board

Valeant Walking Away From Embattled Philidor RX

With an impeccable Wall Street pedigree -- 24 years at Goldman Sachs Group Inc., culminating in a top investment-banking job -- Howard Schiller left for what was fast becoming another palace of deal-making: Valeant Pharmaceuticals International Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.